KRYS - Krystal Biotech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
897.09M
Enterprise Value 3
697.21M
Trailing P/E
N/A
Forward P/E 1
-25.16
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
4.32
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-35.60

Trading Information

Stock Price History

Beta (5Y Monthly) 1.14
52-Week Change 3136.15%
S&P500 52-Week Change 325.98%
52 Week High 366.50
52 Week Low 318.50
50-Day Moving Average 357.77
200-Day Moving Average 347.39

Share Statistics

Avg Vol (3 month) 3161.81k
Avg Vol (10 day) 3168.68k
Shares Outstanding 517.31M
Float 10.03M
% Held by Insiders 133.37%
% Held by Institutions 165.11%
Shares Short (Dec 30, 2019) 41.47M
Short Ratio (Dec 30, 2019) 48.68
Short % of Float (Dec 30, 2019) 415.46%
Short % of Shares Outstanding (Dec 30, 2019) 48.47%
Shares Short (prior month Nov 28, 2019) 41.85M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-9.37%
Return on Equity (ttm)-13.42%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -19.59M
Net Income Avi to Common (ttm)-17.44M
Diluted EPS (ttm)-1.17
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)203.21M
Total Cash Per Share (mrq)11.74
Total Debt (mrq)3.32M
Total Debt/Equity (mrq)1.60
Current Ratio (mrq)54.87
Book Value Per Share (mrq)12.00

Cash Flow Statement

Operating Cash Flow (ttm)-15.19M
Levered Free Cash Flow (ttm)-15.39M